Hitting the right spot: Mechanism of action of OPB-31121, a novel and potent inhibitor of the Signal Transducer and Activator of Transcription 3 (STAT3)

Molecular Oncology

Volumn 9, Issue 6, 2015, Pages 1194-1206

  Brambilla, Lara ^a,e   Genini, Davide ^a   Laurini, Erik ^b   Merulla, Jessica ^a   Perez, Laurent ^c   Fermeglia, Maurizio ^b   Carbone, Giuseppina M ^a,d   Pricl, Sabrina ^b   Catapano, Carlo V ^a,d  

^a INSTITUTE OF ONCOLOGY RESEARCH   (Switzerland)

^b UNIVERSITY OF TRIESTE   (Italy)

^c INSTITUTE FOR RESEARCH IN BIOMEDICINE   (Switzerland)

^d ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^e NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Anticancer drugs; Cancer therapy; Computational modeling; Mechanism of action; Molecular dynamic simulation; Site directed mutagenesis; Small molecule inhibitors; STAT3; Transcription factors

Indexed keywords

ANTINEOPLASTIC AGENT; OPB 31121; STAT3 PROTEIN; UNCLASSIFIED DRUG; STAT3 PROTEIN, HUMAN; TUMOR PROTEIN;

ANTIPROLIFERATIVE ACTIVITY; ARTICLE; BINDING ASSAY; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DRUG BINDING SITE; DRUG MECHANISM; DRUG PROTEIN BINDING; HUMAN; HUMAN CELL; ISOTHERMAL TITRATION CALORIMETRY; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROSTATE CANCER CELL LINE; PROTEIN DOMAIN; PROTEIN PHOSPHORYLATION; SITE DIRECTED MUTAGENESIS; ANTAGONISTS AND INHIBITORS; CHEMISTRY; DRUG EFFECTS; MALE; METABOLISM; MOLECULAR DOCKING; PATHOLOGY; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN TERTIARY STRUCTURE; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MALE; MOLECULAR DOCKING SIMULATION; MOLECULAR DYNAMICS SIMULATION; NEOPLASM PROTEINS; PHOSPHORYLATION; PROSTATIC NEOPLASMS; PROTEIN STRUCTURE, TERTIARY; STAT3 TRANSCRIPTION FACTOR;

EID: 84929514550     PISSN: 15747891     EISSN: 18780261     Source Type: Journal    
DOI: 10.1016/j.molonc.2015.02.012     Document Type: Article

References (54)

1. Becker S., Groner B., Muller C.W. Three-dimensional structure of the Stat3beta homodimer bound to DNA. Nature 1998, 394:145-151.
2. Bendell J.C., Hong D.S., Burris H.A., Naing A., Jones S.F., Falchook G., Bricmont P., Elekes A., Rock E.P., Kurzrock R. Phase 1, open-label, dose-escalation, and pharmacokinetic study of STAT3 inhibitor OPB-31121 in subjects with advanced solid tumors. Cancer Chemother. Pharmacol. 2014, 74:125-130.
3. Benekli M., Baumann H., Wetzler M. Targeting signal transducer and activator of transcription signaling pathway in leukemias. J. Clin. Oncol. 2009, 27:4422-4432.
4. Chan K.S., Sano S., Kiguchi K., Anders J., Komazawa N., Takeda J., DiGiovanni J. Disruption of Stat3 reveals a critical role in both the initiation and the promotion stages of epithelial carcinogenesis. J. Clin. Invest. 2004, 114:720-728.
5. Culig Z., Steiner H., Bartsch G., Hobisch A. Interleukin-6 regulation of prostate cancer cell growth. J. Cell Biochem. 2005, 95:497-505.
6. Debnath B., Xu S., Neamati N. Small molecule inhibitors of signal transducer and activator of transcription 3 (Stat3) protein. J. Med. Chem. 2012, 55:6645-6668.
7. Dhir R., Ni Z., Lou W., DeMiguel F., Grandis J.R., Gao A.C. Stat3 activation in prostatic carcinomas. Prostate 2002, 51:241-246.
8. Fletcher S., Turkson J., Gunning P.T. Molecular approaches towards the inhibition of the signal transducer and activator of transcription 3 (Stat3) protein. ChemMedChem 2008, 3:1159-1168.
9. Genini D., Garcia-Escudero R., Carbone G.M., Catapano C.V. Transcriptional and non-transcriptional functions of PPARbeta/delta in non-small cell lung cancer. PLoS One 2012, 7:e46009.
10. Giliberti G., Ibba C., Marongiu E., Loddo R., Tonelli M., Boido V., Laurini E., Posocco P., Fermeglia M., Pricl S. Synergistic experimental/computational studies on arylazoenamine derivatives that target the bovine viral diarrhea virus RNA-dependent RNA polymerase. Bioorg. Med. Chem. 2010, 18:6055-6068.
11. Gough D.J., Corlett A., Schlessinger K., Wegrzyn J., Larner A.C., Levy D.E. Mitochondrial STAT3 supports Ras-dependent oncogenic transformation. Science 2009, 324:1713-1716.
12. Grivennikov S., Karin M. Autocrine IL-6 signaling: a key event in tumorigenesis?. Cancer Cell 2008, 13:7-9.
13. Guo J., Wang X., Sun H., Liu H., Yao X. The molecular basis of IGF-II/IGF2R recognition: a combined molecular dynamics simulation, free-energy calculation and computational alanine scanning study. J. Mol. Model. 2012, 18:1421-1430.
14. Hayakawa F., Sugimoto K., Harada Y., Hashimoto N., Ohi N., Kurahashi S., Naoe T. A novel STAT inhibitor, OPB-31121, has a significant antitumor effect on leukemia with STAT-addictive oncokinases. Blood Cancer J. 2013, 3:e166.
15. Hedvat M., Huszar D., Herrmann A., Gozgit J.M., Schroeder A., Sheehy A., Buettner R., Proia D., Kowolik C.M., Xin H., Armstrong B., Bebernitz G., Weng S., Wang L., Ye M., McEachern K., Chen H., Morosini D., Bell K., Alimzhanov M., Ioannidis S., McCoon P., Cao Z.A., Yu H., Jove R., Zinda M. The JAK2 inhibitor AZD1480 potently blocks Stat3 signaling and oncogenesis in solid tumors. Cancer Cell 2009, 16:487-497.
16. Kim E., Kim M., Woo D.H., Shin Y., Shin J., Chang N., Oh Y.T., Kim H., Rheey J., Nakano I., Lee C., Joo K.M., Rich J.N., Nam D.H., Lee J. Phosphorylation of EZH2 activates STAT3 signaling via STAT3 methylation and promotes tumorigenicity of glioblastoma stem-like cells. Cancer Cell 2013, 23:839-852.
17. Kim M.J., Nam H.J., Kim H.P., Han S.W., Im S.A., Kim T.Y., Oh D.Y., Bang Y.J. OPB-31121, a novel small molecular inhibitor, disrupts the JAK2/STAT3 pathway and exhibits an antitumor activity in gastric cancer cells. Cancer Lett. 2013, 335:145-152.
18. Kortylewski M., Kujawski M., Wang T., Wei S., Zhang S., Pilon-Thomas S., Niu G., Kay H., Mule J., Kerr W.G., Jove R., Pardoll D., Yu H. Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat. Med. 2005, 11:1314-1321.
19. Kroon P., Berry P.A., Stower M.J., Rodrigues G., Mann V.M., Simms M., Bhasin D., Chettiar S., Li C., Li P.K., Maitland N.J., Collins A.T. JAK-STAT blockade inhibits tumor initiation and clonogenic recovery of prostate cancer stem-like cells. Cancer Res. 2013, 73:5288-5298.
20. Laurini E., Col V.D., Mamolo M.G., Zampieri D., Posocco P., Fermeglia M., Vio L., Pricl S. Homology model and docking-based virtual screening for ligands of the sigma1 receptor. ACS Med. Chem. Lett. 2011, 2:834-839.
21. Laurini E., Marson D., Dal Col V., Fermeglia M., Mamolo M.G., Zampieri D., Vio L., Pricl S. Another brick in the wall. Validation of the sigma1 receptor 3D model by computer-assisted design, synthesis, and activity of new sigma1 ligands. Mol. Pharm. 2012, 9:3107-3126.
22. Lee H., Zhang P., Herrmann A., Yang C., Xin H., Wang Z., Hoon D.S., Forman S.J., Jove R., Riggs A.D., Yu H. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:7765-7769.
23. Lee H.J., Zhuang G., Cao Y., Du P., Kim H.J., Settleman J. Drug resistance via feedback activation of Stat3 in oncogene-addicted cancer cells. Cancer Cell 2014, 26:207-221.
24. Levy D.E., Darnell J.E. Stats: transcriptional control and biological impact. Nat. Rev. Mol. Cell Biol. 2002, 3:651-662.
25. Lim C.P., Cao X. Structure, function, and regulation of STAT proteins. Mol. Biosyst. 2006, 2:536-550.
26. Liu L., McBride K.M., Reich N.C. STAT3 nuclear import is independent of tyrosine phosphorylation and mediated by importin-alpha3. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8150-8155.
27. Marotta L.L., Almendro V., Marusyk A., Shipitsin M., Schemme J., Walker S.R., Bloushtain-Qimron N., Kim J.J., Choudhury S.A., Maruyama R., Wu Z., Gonen M., Mulvey L.A., Bessarabova M.O., Huh S.J., Silver S.J., Kim S.Y., Park S.Y., Lee H.E., Anderson K.S., Richardson A.L., Nikolskaya T., Nikolsky Y., Liu X.S., Root D.E., Hahn W.C., Frank D.A., Polyak K. The JAK2/STAT3 signaling pathway is required for growth of CD44(+)CD24(-) stem cell-like breast cancer cells in human tumors. J. Clin. Invest. 2011, 121:2723-2735.
28. Meier J.A., Larner A.C. Toward a new STATe: the role of STATs in mitochondrial function. Semin. Immunol. 2014, 26:20-28.
29. Miklossy G., Hilliard T.S., Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat. Rev. Drug Discov. 2013, 12:611-629.
30. Mora L.B., Buettner R., Seigne J., Diaz J., Ahmad N., Garcia R., Bowman T., Falcone R., Fairclough R., Cantor A., Muro-Cacho C., Livingston S., Karras J., Pow-Sang J., Jove R. Constitutive activation of Stat3 in human prostate tumors and cell lines: direct inhibition of Stat3 signaling induces apoptosis of prostate cancer cells. Cancer Res. 2002, 62:6659-6666.
31. Morris G.M., Huey R., Lindstrom W., Sanner M.F., Belew R.K., Goodsell D.S., Olson A.J. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J. Comput. Chem. 2009, 30:2785-2791.
32. Napoli S., Pastori C., Magistri M., Carbone G.M., Catapano C.V. Promoter-specific transcriptional interference and c-myc gene silencing by siRNAs in human cells. EMBO J. 2009, 28:1708-1719.
33. O'Shea J.J., Plenge R. JAK and STAT signaling molecules in immunoregulation and immune-mediated disease. Immunity 2012, 36:542-550.
34. Qin H.R., Kim H.J., Kim J.Y., Hurt E.M., Klarmann G.J., Kawasaki B.T., Duhagon Serrat M.A., Farrar W.L. Activation of signal transducer and activator of transcription 3 through a phosphomimetic serine 727 promotes prostate tumorigenesis independent of tyrosine 705 phosphorylation. Cancer Res. 2008, 68:7736-7741.
35. Sansone P., Bromberg J. Targeting the interleukin-6/Jak/stat pathway in human malignancies. J. Clin. Oncol. 2012, 30:1005-1014.
36. Schroeder A., Herrmann A., Cherryholmes G., Kowolik C., Buettner R., Pal S., Yu H., Muller-Newen G., Jove R. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling. Cancer Res. 2014, 74:1227-1237.
37. Schust J., Sperl B., Hollis A., Mayer T.U., Berg T. Stattic: a small-molecule inhibitor of STAT3 activation and dimerization. Chem. Biol. 2006, 13:1235-1242.
38. Sehgal P.B. Paradigm shifts in the cell biology of STAT signaling. Semin. Cell Dev. Biol. 2008, 19:329-340.
39. Shin D.S., Kim H.N., Shin K.D., Yoon Y.J., Kim S.J., Han D.C., Kwon B.M. Cryptotanshinone inhibits constitutive signal transducer and activator of transcription 3 function through blocking the dimerization in DU145 prostate cancer cells. Cancer Res. 2009, 69:193-202.
40. Siddiquee K., Zhang S., Guida W.C., Blaskovich M.A., Greedy B., Lawrence H.R., Yip M.L., Jove R., McLaughlin M.M., Lawrence N.J., Sebti S.M., Turkson J. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 2007, 104:7391-7396.
41. Song H., Wang R., Wang S., Lin J. A low-molecular-weight compound discovered through virtual database screening inhibits Stat3 function in breast cancer cells. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:4700-4705.
42. Sos M.L., Levin R.S., Gordan J.D., Oses-Prieto J.A., Webber J.T., Salt M., Hann B., Burlingame A.L., McCormick F., Bandyopadhyay S., Shokat K.M. Oncogene mimicry as a mechanism of primary resistance to BRAF inhibitors. Cell Rep. 2014, 8:1037-1048.
43. Su Y.J., Lai H.M., Chang Y.W., Chen G.Y., Lee J.L. Direct reprogramming of stem cell properties in colon cancer cells by CD44. EMBO J. 2011, 30:3186-3199.
44. Timofeeva O.A., Chasovskikh S., Lonskaya I., Tarasova N.I., Khavrutskii L., Tarasov S.G., Zhang X., Korostyshevskiy V.R., Cheema A., Zhang L., Dakshanamurthy S., Brown M.L., Dritschilo A. Mechanisms of unphosphorylated STAT3 transcription factor binding to DNA. J. Biol. Chem. 2012, 287:14192-14200.
45. Toso A., Revandkar A., Di Mitri D., Guccini I., Proietti M., Sarti M., Pinton S., Zhang J., Kalathur M., Civenni G., Jarrossay D., Montani E., Marini C., Garcia-Escudero R., Scanziani E., Grassi F., Pandolfi P.P., Catapano C.V., Alimonti A. Enhancing Chemotherapy efficacy in Pten-Deficient prostate tumors by activating the Senescence-associated antitumor immunity. Cell Rep. 2014, 9:75-89.
46. Wegrzyn J., Potla R., Chwae Y.J., Sepuri N.B., Zhang Q., Koeck T., Derecka M., Szczepanek K., Szelag M., Gornicka A., Moh A., Moghaddas S., Chen Q., Bobbili S., Cichy J., Dulak J., Baker D.P., Wolfman A., Stuehr D., Hassan M.O., Fu X.Y., Avadhani N., Drake J.I., Fawcett P., Lesnefsky E.J., Larner A.C. Function of mitochondrial Stat3 in cellular respiration. Science 2009, 323:793-797.
47. Wen Z., Zhong Z., Darnell J.E. Maximal activation of transcription by Stat1 and Stat3 requires both tyrosine and serine phosphorylation. Cell 1995, 82:241-250.
48. Xu F., Mukhopadhyay S., Sehgal P.B. Live cell imaging of interleukin-6-induced targeting of "transcription factor" STAT3 to sequestering endosomes in the cytoplasm. Am. J. Physiol. Cell Physiol. 2007, 293:C1374-C1382.
49. Yang J., Liao X., Agarwal M.K., Barnes L., Auron P.E., Stark G.R. Unphosphorylated STAT3 accumulates in response to IL-6 and activates transcription by binding to NFkappaB. Genes Dev. 2007, 21:1396-1408.
50. Yu H., Lee H., Herrmann A., Buettner R., Jove R. Revisiting STAT3 signalling in cancer: new and unexpected biological functions. Nat. Rev. Cancer 2014, 14:736-746.
51. Yu H., Pardoll D., Jove R. STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 2009, 9:798-809.
52. Yuan Z.L., Guan Y.J., Chatterjee D., Chin Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005, 307:269-273.
53. Zhang X., Blenis J., Li H.C., Schindler C., Chen-Kiang S. Requirement of serine phosphorylation for formation of STAT-promoter complexes. Science 1995, 267:1990-1994.
54. Zhong Z., Wen Z., Darnell J.E. Stat3: a STAT family member activated by tyrosine phosphorylation in response to epidermal growth factor and interleukin-6. Science 1994, 264:95-98.